Both TSC and sporadic LAM result from germline or somatic TSC1/TSC2 mutations, respectivly5,6 that prevent the inhibition of the mechanistic target of rapamycin (mTOR) by TSC1/TSC2 complex7,8. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.